For this reason, there is an increasing interest in the evaluation of molecules with pharmacological activities against cancer cells, such as metalloproteinases, vascular growth factors, phospholipases A2 (PLA2), cysteine-rich secretory proteins, L-amino acid oxidases, small peptides, C-type lectins, and disintegrins. This evidence concerns the gene IL4I1 and cancer.